<DOC>
	<DOCNO>NCT01190189</DOCNO>
	<brief_summary>This extension study design ass safety GSK Biological 's human papillomavirus ( HPV ) vaccine GSK580299 female subject take part primary study NCT00294047 receive control vaccine country license GSK HPV vaccine indicate subject 's age group ( 26 year old ) . This study thus conduct enable woman receive control placebo primary NCT00294047 study receive GSK580299 vaccine .</brief_summary>
	<brief_title>Safety Evaluation GSK-580299 Vaccine Women From Control Group Primary NCT00294047 Study</brief_title>
	<detailed_description>This Protocol Posting update follow Protocol Amendment 1 , December 2010 , lead update 1 primary outcome measure follow Protocol Amendment 2 , January 2011 , lead removal one exclusion criterion .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol A subject previously enrol study NCT00294047 , receive control vaccine , receive GSK580299 vaccine subject age vaccine license . Written inform consent obtain subject Free obvious health problem establish medical history clinical examination enter study . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Pregnant breastfeeding . A woman plan become pregnant , likely become pregnant planning discontinue contraceptive precaution vaccination phase study , i.e . two month last vaccine dose . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Previous vaccination HPV plan administration another HPV vaccine study foreseen protocol . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . For corticosteroid , mean prednisone great equal 20 mg/day , equivalent . Inhaled topical steroid allow Planned administration/administration vaccine foreseen study protocol within 30 day ( i.e. , Day 029 ) dose vaccine , exception administration routine meningococcal , hepatitis B , hepatitis A , inactivated influenza , diphtheria/tetanus and/or diphtheria/tetanuscontaining vaccine 8 day dose study vaccine . Enrolment defer subject outside specify window . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . NOTE : Subjects enrol study may also eligible fouryear gynaecological followup HPV015 study , investigational product administer . Subjects invite gynaecological followup study either follow applies : test positive oncogenic HPV infection , display normal cervical cytology conclude HPV015 study end visit ; pregnant cervical sample take conclude HPV015 study end visit ; Previous administration component vaccine . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Cancer autoimmune disease treatment . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period . History reaction hypersensitivity likely exacerbate component vaccine History neurological disorder seizure . Acute disease and/or fever time enrolment . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test .</criteria>
	<gender>Female</gender>
	<minimum_age>26 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Serious adverse event ( SAEs )</keyword>
	<keyword>HPV vaccine</keyword>
	<keyword>Medically significant condition</keyword>
	<keyword>Cervical neoplasia</keyword>
</DOC>